2.60Open2.60Pre Close0 Volume4 Open Interest15.00Strike Price0.00Turnover129.07%IV9.93%PremiumJan 17, 2025Expiry Date1.01Intrinsic Value100Multiplier8DDays to Expiry1.59Extrinsic Value100Contract SizeAmericanOptions Type0.6677Delta0.1148Gamma8.89Leverage Ratio-0.0700Theta0.0021Rho5.94Eff Leverage0.0089Vega
MediWound Stock Discussion
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
Tuesday, 17th December at 8:00 am
YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. T...
·3 mins ago
Mediwound Announces U.S. Food and Drug Administration Approval of Nexobrid® for the Treatment of Pediatric Patients With Severe Thermal Burns
No comment yet